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Abstract
Background: One of the most important challenges in the study of aging is to discover compounds with longevity-
promoting activities and to unravel their underlying mechanisms. Royal jelly (RJ) has been reported to possess diverse
beneficial properties. Furthermore, protease-treated RJ (pRJ) has additional pharmacological activities. Exactly how RJ and
pRJ exert these effects and which of their components are responsible for these effects are largely unknown. The
evolutionarily conserved mechanisms that control longevity have been indicated. The purpose of the present study was to
determine whether RJ and its related substances exert a lifespan-extending function in the nematode Caenorhabditis
elegans and to gain insights into the active agents in RJ and their mechanism of action.
Principal Findings: We found that both RJ and pRJ extended the lifespan of C. elegans. The lifespan-extending activity of
pRJ was enhanced by Octadecyl-silica column chromatography (pRJ-Fraction 5). pRJ-Fr.5 increased the animals’ lifespan in
part by acting through the FOXO transcription factor DAF-16, the activation of which is known to promote longevity in C.
elegans by reducing insulin/IGF-1 signaling (IIS). pRJ-Fr.5 reduced the expression of ins-9, one of the insulin-like peptide
genes. Moreover, pRJ-Fr.5 and reduced IIS shared some common features in terms of their effects on gene expression, such
as the up-regulation of dod-3 and the down-regulation of dod-19, dao-4 and fkb-4. 10-Hydroxy-2-decenoic acid (10-HDA),
which was present at high concentrations in pRJ-Fr.5, increased lifespan independently of DAF-16 activity.
Conclusions/Significance: These results demonstrate that RJ and its related substances extend lifespan in C. elegans,
suggesting that RJ may contain longevity-promoting factors. Further analysis and characterization of the lifespan-extending
agents in RJ and pRJ may broaden our understanding of the gene network involved in longevity regulation in diverse
species and may lead to the development of nutraceutical interventions in the aging process.
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Introduction
Lifespan in metazoans is influenced not only by genetic factors
[1], [2] but also by environmental factors, including temperature
[3], [4], oxygen [5–7], food intake [8] and nutrition [9–16]. In the
honeybee Apis mellifera L., queens live and reproduce for 1–4 years,
yet hive workers, which are derived from the same diploid
genome, live for only 3–6 weeks during the spring and summer in
temperate climates [17–19]. Queens are fed throughout their lives
with royal jelly (RJ), which is produced by the hypopharyngeal,
postcerebral and mandibular glands of the worker bees. In
contrast, workers are fed this RJ for only a short period of time
during their larval stages. This scenario raises the possibility that
RJ contains longevity-promoting agents for queens [17], [19]. An
analysis of its chemical composition showed that RJ comprises
proteins, sugars, lipids, vitamins and free amino acids [20] together
with a variety of bioactive substances, including AMP N1-oxide
[21], peptides [22–24], acetylcholine [25–27] and fatty acids, such
as 10-hydroxy-2-decenoic acid (10-HDA) [28]. The mechanism by
which RJ exerts its longevity effects on queen bees and the
identities of the components that play critical roles in this process
are largely unknown.
Lifespan-control mechanisms involving biological responses to
hormonal or nutritional signals are remarkably conserved, even in
diverse species, including nematodes, insects and mammals [2].
The effects of RJ on the extension of lifespan are likewise
conserved between Drosophila [9] and mice [29], indicating that RJ
plays the same role in disparate phyla.
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pharmacological activities such as antibacterial [30], antitumor
[31], anti-allergic [32], antifatigue [33], anti-inflammatory [34],
[35] and immunomodulatory [36], [37] effects. RJ also induces
neurite outgrowth [38], prevents dermatitis [39], hypercholester-
olemia [40] and osteoporosis [41] and stimulates bone formation
[42]. Protease-treated RJ (pRJ) has additional beneficial proper-
ties, including antioxidant activity [43], inhibitory effects on lipid
peroxidation [44] and antihypertensive effects [45–47].
The nematode Caenorhabditis elegans has been widely used in
studies on aging and longevity. It is an ideal model organism for
such studies because of its relatively short lifespan (3–4 weeks) and
well-established genetic pathways [1]. Using C. elegans, researchers
have identified several compounds that are capable of extending
lifespan and are derived from natural products including
blueberries [48], herbs [49] and green tea [50], [51]. In the
present study, we examined the effects of RJ and pRJ on the
lifespan of C. elegans to identify the lifespan-extending agents in
these substances and to understand the mechanism of their action.
Results
Effects of RJ on the lifespan of C. elegans
We first investigated the effects of RJ on the lifespan of the wild-
type N2 strain of C. elegans. RJ treatment was begun at the young
adult stage with concentrations ranging from 1 to 100 mg/ml. RJ
treatment at 10 mg/ml extended the mean lifespan by 7–9%,
whereas either 1 or 100 mg/ml RJ had little or no effects on the
lifespan (Fig. 1, Table S1), indicating that there is an optimal dose
of RJ for lifespan extension. In contrast, pRJ prolonged the mean
lifespan at all concentrations tested (1, 10 and 100 mg/ml). The
maximal effect was observed at 10 mg/ml, at which concentration
the mean lifespan was increased by 7–18% (Fig. 2, Table S1).
These results suggest that both RJ and pRJ contain the lifespan-
extending agents and that these agents are not proteinaceus.
To gain insights into the nature of the lifespan-extending agents,
we performed fractionations of both RJ and pRJ. RJ was divided
into EtOH-soluble (RJ-Fr.1) and water-soluble (RJ-Fr.2) fractions.
Neither of these fractions extended the lifespan (Fig. S1, Fig. S2,
Table S1). pRJ was fractionated by Octadecyl-silica (ODS) column
chromatography and eluted with water (pRJ-Fr.4) and subse-
quently with 30% MeOH (pRJ-Fr.5). pRJ-Fr.4 at concentrations
from 5 to 100 mg/ml increased the mean lifespan (Fig. 3, Table
S1). The maximal effect was observed at 10 mg/ml, at which
concentration the mean lifespan was increased by 9%. In contrast,
pRJ-Fr.5 at concentrations of 10, 25 and 100 mg/ml increased the
mean lifespan by 8–9%, 18–19% and 17–19%, respectively (Fig. 4,
Table S1). These results indicated that the lifespan-extending
agents in pRJ were enriched in the 30% MeOH-eluted fraction
more than in the water-eluted fraction.
Gene expression changes during pRJ-Fr.5 treatment
To understand the mechanism underlying the lifespan extension
by pRJ-Fr.5, we analyzed genome-wide changes in gene
expression during treatment of C. elegans N2 with pRJ-Fr.5. Using
the Agilent C. elegans (V2) Gene Expression Microarray, we
monitored the expression of 20,000 genes. To identify differen-
tially regulated genes, we eliminated all probes with absent or
marginal flags and then performed a t-test with the significance
level set at p,0.05. Of these genes, 733 were further selected using
the criterion of at least a 1.8-fold change (Table S2). Further
analysis of these 733 genes revealed that pRJ-Fr.5 down-regulated
ins-9 and up-regulated ins-20 and ins-23, all of which encode
insulin-like peptides (Table S2). Among these insulin-like peptide
genes, real-time RT-PCR confirmed down-regulation of ins-9 gene
expression after pRJ-Fr.5 treatment (Fig. 5). These results are
consistent with previous findings implicating reduced insulin/IGF-
1 signaling (IIS) in lifespan extension [1]. pRJ-Fr.5 also down-
regulated dod-19, dao-4, and fkb-4 and up-regulated dod-3 (Table
S2). These expression changes were all verified by real-time RT-
PCR analysis (Fig. 5) and, more importantly, correlated with the
changes observed when IIS is reduced in C. elegans [52], [53].
Certain DNA motifs were previously reported to be associated
with the FOXO transcription factor DAF-16 [53], [54], the
activation of which is known to promote longevity in C. elegans
upon reduction of IIS [1]. The DAF-16-binding element (DBE:
TTGTTTAC) [54] and the DAF-16-associated element (DAE:
CTTATCA) [53] were overrepresented in the upstream regions of
ins-9, dod-3, dod-19, dao-4 and fkb-4 (Table 1), suggesting that their
gene expression is controlled by DAF-16 activity.
Effects of pRJ-Fr.5 on lifespan in daf-16 deletion mutants
To clarify whether the IIS-DAF-16 pathway is involved in pRJ-
Fr.5-induced extension of lifespan, we examined the effects of pRJ-
Fr.5 on the lifespan of a daf-16 deletion mutant. The findings that
pRJ-Fr.5 extended the mean lifespan of this mutant by 8–12%
(Fig. 6, Table S1) and that this effect was smaller than that
observed in wild-type N2 (18–19%) (Fig. 4, Table S1) indicated
that pRJ-Fr.5 extends the lifespan by both IIS-DAF-16 pathway-
dependent and -independent mechanisms.
Effects of pRJ-Fr.5 on DAF-16 nuclear translocation
To ascertain whether pRJ-Fr.5 acts on the IIS-DAF-16
pathway, we examined the effects of pRJ-Fr.5 treatment on
DAF-16 nuclear localization, which has been shown to be
augmented when IIS is abrogated [55], [56]. We found that
pRJ-Fr.5 treatment induced DAF-16 nuclear localization (Fig. S3),
suggesting that pRJ-Fr.5 acts on the IIS-DAF-16 pathway.
Analysis of pRJ-Fr.5 components
Next, we analyzed the components of pRJ-Fr.5. The amount of
sugars contained in pRJ-Fr.5 was estimated to be 20%(w/w) in
terms of glucose. Peptides accounted for more than 60%(w/w) of
pRJ-Fr.5. The molecular weight measurement indicated that pRJ-
Fr.5 contained low-molecular weight peptides, such as dipeptides
and tripeptides, as well as 16.5% (w/w) 10-HDA. We also
measured the 10-HDA content in RJ, pRJ and the other fractions
derived from them. The 10-HDA concentrations were as follows:
RJ: 1.7%, pRJ: 5.3%, RJ-Fr.1: 8.9%, RJ-Fr.2: 2.1% and pRJ-Fr.4:
,0.1%. These results showed that 10-HDA was enriched
especially in pRJ-Fr.5.
Effects of 10-HDA on lifespan in N2 and daf-16 deletion
mutants
To elucidate whether 10-HDA is a lifespan-extending agent, we
assessed its effects on lifespan. Worms treated beginning at the
young adult stage with concentrations of 10-HDA ranging from 10
to 100 mM all showed extensions of the mean and maximum
lifespans (Fig. 7, Table S3). The largest increase was observed at
25 mM, at which concentration the mean lifespan was increased by
12%.
We next tested whether 10-HDA extends lifespan through the
IIS-DAF-16 pathway by measuring the effects of this compound
on the lifespan of the daf-16 deletion mutants. 10-HDA at
concentrations from 10 to 100 mM extended the mean lifespan of
this mutant by 6–15% (Fig. 8, Table S3). The ability of 10-HDA to
extend the lifespan of the daf-16 deletion mutants and the wild-
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extending effect is mediated through a mechanism independent of
the IIS-DAF-16 pathway.
Effects of combined treatment with pRJ-Fr.5 and 10-HDA
on lifespan
To examine the contribution of 10-HDA to pRJ-Fr.5-induced
lifespan extension, we tested the effect of combining pRJ-Fr.5 and
10-HDA on lifespan. The lifespan extension achieved by the
combination of pRJ-Fr.5 and 10-HDA was greater than that
induced by each treatment alone, but the effect was less than
additive (Fig. 9, Table S3). These results suggest that pRJ-Fr.5 and
10-HDA do not extend lifespan independently of each other.
Therefore, part of the lifespan extension by pRJ-Fr.5 is probably
due to its 10-HDA component.
Discussion
The present study demonstrates that RJ has the ability to
prolong the lifespan of C. elegans (Fig. 1), as it is known to do in
Drosophila [9] and mice [29], suggesting that RJ may contain
longevity-promoting factors that can act in diverse species across
phyla. This lifespan-extending activity of RJ in C. elegans was not
diminished by protease treatment of RJ (Fig. 2), indicating that
proteins in RJ are not responsible for the lifespan extension. The
water-eluted fraction of pRJ (pRJ-Fr.4) had some lifespan-
extending activity (Fig. 3), suggesting that water-soluble com-
pounds, such as sugars, amino acids, vitamins or peptides
including protein-proteolysis products, may have such activity.
Although RJ could extend lifespan (Fig. 1, Table S1), neither the
EtOH-soluble (RJ-Fr.1) nor the water-soluble (RJ-Fr.2) fraction of
RJ exhibited lifespan-extending activity (Fig. S1, Fig. S2). It is
Figure 1. The effects of RJ on the lifespan of C. elegans. The survival curves of N2 hermaphrodites treated with RJ (0 (control), 1, 10 or 100 mg/
ml) are shown. These substances were administered at 20uC, from the young adult stage until death. Day 0 corresponds to the L4 molt. The
percentage of live worms is plotted against adult age. Detailed parameters are presented in Table S1.
doi:10.1371/journal.pone.0023527.g001
Figure 2. The effects of pRJ on the lifespan of C. elegans. The survival curves of N2 hermaphrodites treated with pRJ (0 (control), 1, 10 or
100 mg/ml) are shown. The experiment was performed as described in Figure 1 Legend. Detailed parameters are presented in Table S1.
doi:10.1371/journal.pone.0023527.g002
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Fr.2. One possibility is that the concentrations of the lifespan-
extending agents in RJ-Fr.1 and RJ-Fr.2 used in this study may be
above or below the narrow dose range that can extend lifespan.
We found that 10-HDA extended the lifespan of C. elegans
(Fig. 7). This is the first evidence that 10-HDA, a defined natural
component of RJ, can extend organismal lifespan. 10-HDA is
known to have several pharmacological activities such as
antibacterial [57], antitumor [58], anti-inflammatory [59], and
anti-angiogenic [60] as well as the ability to promote neurogenesis
[61] and collagen production [62]. Additionally, 10-HDA is
known to possess growth-inhibitory activity in honeybee queens
[63]. The present observations demonstrate that 10-HDA can also
perform more integrative functions, such as extending organismal
lifespan.
The 30% MeOH-eluted fraction of pRJ (pRJ-Fr.5) generated by
ODS column chromatography exhibited higher lifespan-extending
activity than did pRJ-Fr.4 (Fig. 3, Fig. 4, Table S1). This result can
be partly explained by the higher concentration of 10-HDA in
pRJ-Fr.5. Furthermore, the finding that the lifespan extension
induced by both pRJ-Fr.5 and 10-HDA was greater than that
induced by each treatment alone but was less than additive (Fig. 9,
Table S3) suggests that part of the lifespan extension by pRJ-Fr.5
was likely due to the 10-HDA contained in pRJ-Fr.5.
A variety of intricate regulatory networks have been shown to
control lifespan [2]. Among them, IIS has been well established as a
fundamental pathway that regulates the lifespan of C. elegans,
Drosophila and mice [64]. It has been suggested that this pathway is a
key determinant of the lifespan differences between honeybee
queens and workers [65]. Reduced IIS extends the lifespan through
Figure 3. The effects of pRJ-Fr.4 on the lifespan of C. elegans. The survival curves of N2 hermaphrodites treated with pRJ Fr.4 (0 (control), 5, 10
or 25 mg/ml) are shown. The experiment was performed as described in Figure 1 Legend. Detailed parameters are presented in Table S1.
doi:10.1371/journal.pone.0023527.g003
Figure 4. The effects of pRJ-Fr.5 on the lifespan of C. elegans. Survival curves of N2 hermaphrodites treated with pRJ-Fr.5 (0 (control), 10, 25 or
100 mg/ml). The experiment was performed as described in Figure 1 Legend. Detailed parameters are presented in Table S1.
doi:10.1371/journal.pone.0023527.g004
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found that pRJ-Fr.5 induced nuclear localization of DAF-16 (Fig.
S3), indicating that pRJ-Fr.5 activated DAF-16. However, our
results showed that the mean-lifespan extension by pRJ-Fr.5 in N2
was greater than that in the daf-16 deletion mutant (Fig. 3, Fig. 4,
Table S1), indicating that pRJ-Fr.5 extended the lifespan by both
DAF-16-dependent and DAF-16-independent mechanisms. This
finding is consistent with the notion that pRJ-Fr.5 extends the
lifespan in part through the IIS-DAF-16 pathway and in part
through some other mechanism.
We performed DNA microarray and real-time RT-PCRanalyses
toidentify pRJ-Fr.5-regulatedgenes.Inthesegenes,ins-9wasdown-
regulated by pRJ-Fr.5. Among the 40 known insulin-like peptides in
C. elegans, INS-1 [69], INS-7 [53], INS-11 [70], INS-18 [71] and
DAF-28 [72], [73] have been reported to be regulators of lifespan.
Similar to ins-1 and daf-28, ins-9 is also expressed in chemosensory
neurons such as ASI [74], which plays an important role in lifespan
determination [74], [75]. Interestingly, the expression of ins-7 has
been reported to be regulated by IIS-DAF-16 [76]. We also
suggested that ins-9 expression is also controlled by IIS-DAF-16
from the finding that the DBE and DAE are overrepresented in the
upstream regions of ins-9 (Table 1).
We also found that pRJ-Fr. 5 down-regulated dod-19, dao-4 and
fkb-4 and up-regulated dod-3 (Fig. 5, Table S2), gene expression
changes that are also observed when IIS is reduced [52], [53]. The
dod-19geneencodesanunknownprotein;however,intriguingly,itis
one of the known determinants of lifespan [53]. It is also interesting
to note that fkb-4 encodes a homolog of the mammalian protein
FKBP [52], which binds to the immunosuppressant FK506 and
rapamycin. FKBP is involved in the mammalian target of
rapamycin (TOR) pathway [77–82] and in diverse cellular
functions, including protein folding and the modulation of oxidative
stress [83]. FKBP also has neural roles [84], [85]. Inhibition of the
TOR pathway has been found to increase lifespan in a variety of
species, including yeast, nematodes, flies, and mice [86–91]. The
deletion of both fkb-4 and fkb-5, another FKBP gene, results in
lethality under cold conditions [92], and it has been observed that
cold conditions affect lifespan in C. elegans [3]. Interestingly, the
TOR pathway works as an energy- and nutrient-sensing pathway to
determine the queen/worker differentiation in honeybees [93].
Further research is necessary to determine whether these genes are
actually involved in the lifespan extension mediated by pRJ-Fr.5.
Recent investigations have provided evidence of common
longevity regulation pathways between nematodes, insects and
Figure 5. The effects of pRJ-Fr.5 treatment on gene expression in C. elegans. Relative expression levels of genes (ins-9, dod-3, dod-19, dao-4,
and fkb-4) in N2 hermaphrodites treated with pRJ-Fr.5 (0 (control) or 25 mg/ml) for 24 h starting at the L4 stage. Data are expressed as the mean 6 S.E.
(n=3). *: p,0.05; **: p,0.01, compared with control (Student’s t test).
doi:10.1371/journal.pone.0023527.g005
Table 1. DAF-16 promoter elements in the upstream region
of genes commonly regulated by reduced IIS and pRJ-Fr.5.
Gene Cosmid no.
DBE
TTGTTTAC
DAE
CTTATC
dod-3 C24B9.9 3 1
dod-19 ZK6.10 1 3
fkb-4 ZC455.10 1 1
dao-4 ZC373.6 1 1
ins-9 C06E2.8 2 2
The number of DAF-16-binding elements and DAF-16-associated elements in
the 2kb upstream of each gene is shown.
doi:10.1371/journal.pone.0023527.t001
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characterization of the longevity-promoting compounds contained
in RJ will broaden our understanding of the gene networks involved
in longevity regulation in diverse species and may lead to the
development of nutraceutical interventions in the aging process.
Materials and Methods
Nematode strains and culture conditions
The C. elegans strains were maintained at 20uC on nematode
growth medium (NGM) agar with Escherichia coli OP50 as a food
source, as previously described [94]. The N2 Bristol strain was used
as the wild-type C. elegans. The mutant strain used in this study was
CF1038: daf-16(mu86) I and TJ356: zIs356 [Ex(daf-16::gfp + rol-6)].
Royal jelly and protease treatment
Fresh RJ, which was produced by honeybees (Apis mellifera L.)
foraging on Brassica sp. in China, was obtained from Api Co., Ltd.,
Gifu, Japan. RJ hydrolyzed by Protease N (pRJ) was prepared as
previously described [95]. The following drugs and chemicals were
purchased and used: 10-HDA (Alfresa Pharma Co., Ltd., Osaka,
Japan) and Protease N ‘‘Amano’’ (from Bacillus subtilis; Amano
Enzyme Inc. Aichi, Japan).
Fractionation of RJ
Fresh RJ (1 kg) was mixed with water (1 L), hexane (2 L) and
EtOH (4 L), and then shaken slowly overnight at room
temperature. This mixture was filtered through No. 2 filter paper
and then the extracts were concentrated under pressure until they
Figure 6. The effects of pRJ-Fr.5 on the lifespan of daf-16(mu86) mutants. The survival curves of daf-16(mu86) mutant hermaphrodites
treated with pRJ-Fr.5 (0 (control) or 25 mg/ml). The experiment was performed as described in Figure 1 Legend. Detailed parameters are presented in
Table S1.
doi:10.1371/journal.pone.0023527.g006
Figure 7. The effects of 10-HDA on the lifespan of C. elegans. The survival curves of N2 hermaphrodites incubated with 10-HDA (0 (control), 10,
25, 50 or 100 mM) are shown. The experiment was performed as described in Figure 1 Legend. Detailed parameters are presented in Table S3.
doi:10.1371/journal.pone.0023527.g007
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heating under reduced pressure and then mixed with 5% EtOH.
The supernatant from this suspension was then freeze-dried (RJ-
Fr.1). The yields of RJ-Fr.1 and RJ-Fr.2 were 40.9% and 16.0%,
respectively.
Fractionation of pRJ
pRJ (20 g) was mixed with water and then chromatographed on
an ODS column. The column was eluted stepwise with water and
30% (v/v) aqueous MeOH. Each fraction (1 L each) was collected
and freeze-dried. These fractions were designated as pRJ-Fr.4
(15 g in the H2O phase) and pRJ-Fr.5 (3.8 g in the 30% MeOH
phase).
Determination of lifespan
Eggs that were isolated with hypochlorite were placed on fresh
NGM agar plates containing UV-killed E. coli strain OP50, unless
otherwise stated. UV-killing was used to avoid any effects of live E.
coli on the compounds examined in this study and any effects of
these compounds on growth of live E.coli. To kill the OP50, plates
covered with OP50 were UV-irradiated as previously described
[96]. Worms were raised until the L4 molt and were subsequently
transferred onto a new plate containing 40 mM 5-fluoro-29-
deoxyuridine (FUdR, Sigma Aldrich, St. Louis, MO, USA) to
prevent self-fertilization. The day of transfer at the L4 molt was
counted as 0-day adult in the lifespan assay. The worms were
transferred to fresh plates daily, and the number of surviving
Figure 8. The effects of 10-HDA on the lifespan of daf-16(mu86) mutants. The survival curves of daf-16(mu86) mutant hermaphrodites
incubated with 10-HDA (0 (control), 10, 25, 50 or 100 mM) are shown. The experiment was performed as described in Figure 1 Legend. Detailed
parameters are presented in Table S3.
doi:10.1371/journal.pone.0023527.g008
Figure 9. The effects of 10-HDA and/or pRJ-Fr.5 on the lifespan of C. elegans. The survival curves of N2 hermaphrodites incubated with 10-
HDA (0 or 25 mM) and/or pRJ-Fr.5 (0 or 25 mg/ml) are shown. The experiment was performed as described in Figure 1 Legend. Detailed parameters
are presented in Table S3.
doi:10.1371/journal.pone.0023527.g009
Lifespan-Extending Effects of Royal Jelly
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were judged to be dead when they did not respond to a
mechanical stimulus. To focus on aging, worms that had become
desiccated on the side of the plate after crawling off, that displayed
extruded internal organs or that died because of progeny hatching
inside the uterus (matricidal death) were excluded from our
analysis. The results of the survival assays were analyzed using the
Kaplan-Meier method, and significance was measured with the
log-rank test using the statistical analysis package StatMate III
(ATMS, Tokyo, Japan).
Treatment with compounds
EtOH solutions of RJ, pRJ and RJ-Fr.1, aqueous solutions of
RJ-Fr.2, pRJ-Fr.4 and pRJ-Fr.5 as well as 10-HDA in DMSO,
were added to liquid NGM that had been autoclaved and cooled
to 50uC. The media were immediately dispensed into Petri dishes.
Experiments involving RJ, pRJ and RJ-Fr.1 were performed in
parallel with those involving a control group treated with 0.1%
EtOH; and experiments involving 10-HDA were conducted in
parallel with those involving a control group treated with 0.03%
DMSO.
DNA microarray analysis
The C. elegans N2 strains were treated with pRJ-Fr.5 (0 (control)
or 25 mg/ml) for 24 h beginning at the L4 stage. A total of 8,000-
10,000 worms were collected for each sample. The worms were
homogenized in TRIzolH Reagent (Invitrogen
TM, Carlsbad, CA)
using a Precellys 24 (Bertin Technologies, Montigny-le-Breton-
neux, France). Total RNA was extracted with a PureLink
TM RNA
Mini kit (Invitrogen
TM). The Agilent C. elegans (V2) Gene
Expression Microarray, 4x44K (G2519F-020186) was used for
global gene expression analysis. This microarray contains 43,803
C. elegans complementary DNA (cDNA) probes, each consisting of
a single 60-oligomer oligonucleotide sequence. Target RNA
labeling and hybridization were performed according to the
protocol for one-color microarray-based gene expression analysis
using the Quick Amp Labeling Kit (Agilent Technologies, Santa
Clara, CA). In brief, 500 ng of RNA was transcribed using the
oligo(dT)-based T7 promoter primer and MMLV-RT in the first-
and second-strand cDNA synthesis reactions. The double-stranded
cDNAs were used as templates for the preparation of fluorescent
complementary RNAs (cRNAs) in the presence of T7 RNA
polymerase and cyanine 3-CTP dye in an in vitro transcription
reaction. The labeled cRNAs were purified, fragmented, and
hybridized to microarrays in a rotating hybridization oven at
10 rpm for 17 h at 65uC. After hybridization, the microarrays
were washed according to the manufacturer’s instructions and
scanned using an Agilent DNA Microarray Scanner with Scan
Control software (Agilent Technologies). The resulting images
were processed, and the raw data were collected using the Agilent
Feature Extraction software. The gene expression data were
analyzed using GeneSpring GX 11 (Agilent Technologies). The
signal intensity of each probe was normalized by a percentile shift,
in which each value was divided by the 75th percentile of all the
values in its array. The microarray data discussed in this
publication have been deposited in NCBI’s Gene Expression
Omnibus (GEO) and are accessible through the GEO Series
accession number GSE26094 (http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE26094). To identify the genes with
biological significance, we applied flags attributed to the signal
intensity of each probe, the fold change, and the Student’s t-test
values. All the data are MIAME compliant.
Real-time RT-PCR analysis
Total RNA was reverse-transcribed to cDNA using a High
Capacity cDNA Reverse Transcription kit (Applied Biosystems),
and subjected to real-time PCR using the SYBR Premix Ex Taq II
(Perfect Real Time) (TaKaRa) and the Thermal Cycler Dice Real
Time System (TaKaRa). The following primers were used: ins-9
forward, 59-GGCGAGAAGAACCTTGGAAAC-39; ins-9 reverse,
59-ACAGCACAGCTTAGAGAGATCCTG-39; ins-20 forward,
59-TCATCATCACAGGCACAAAGG-39; ins-20 reverse, 59-GC-
AAAATATCATCATCCGTCAGG-39; ins-23 forward, 59-CAG-
AGCTTCACGTTCGTAGGG-39; ins-23 reverse, 59-GAACAG-
TACTCGGTTGGACTTGG-39; dod-3 forward, 59-AAGCCAT-
GTTCCCGAATGAG-39; dod-3 reverse, 59-GCTGCGAAAAG-
CAAGAAAATG-39; dod-19 forward, 59-ACCGTTCCCAGTTT-
TACAGTCC-39; dod-19 reverse, 59-TATTTTGAGGCGCGGA-
TACAC-39; dao-4 forward, 59-GCACATTACAAATGCTTCA-
AGGAC-39; dao-4 reverse, 59-TGACACCCTCATCCCCATA-
AC-39; fkb-4 forward, 59-CTATGCGAGGAATGTGTATTG-
GAG-39; fkb-4 reverse, 59-TGGACAGTGTAATAGAGTGGCT-
GAC-39; rla-1 forward, 59-ACCGGCGAGAAGATCGCTAC-39;
rla-1 reverse, 59-CGGAAGAGACAGAAGTGATGAGG-39. The
relative expression level of each gene was calculated using the
comparative Ct method. Ribosomal protein, Large subunit, Acidic
(P1) family member (rla-1) was used as an internal control gene.
Analysis of pRJ-Fr.5 components
Sugar content was estimated by orcinol/sulfuric acid analysis.
Peptide content was estimated by the Lowry method. The
molecular weights of peptides were estimated by HPLC analysis
on a Superdex Peptide HR 10/30 column (Pharmacia Biotech,
Uppsala, Sweden). The 10-HDA content was determined using
HPLC with a Consmosil 5C18-MS-II column (Nacalai Tesque,
Tokyo, Japan) at 40uC. The column was eluted with a mobile
phase of 10 mM phosphate buffer (pH 2.5) and MeOH
(1960:1540, v/v) at a flow rate of 1.0 ml/min.
Supporting Information
Figure S1 The effect of RJ-Fr.1 on the lifespan of C. elegans. The
survival curves of N2 hermaphrodites incubated with RJ-Fr.1 (0
(control), 10, 25 or 100 mg/ml) are shown. The RJ-Fr.1 was given
at 20uC from 0-day adult until death. Day 0 corresponds to the L4
molt. The percentage of live worms is plotted against adult age.
Detailed parameters are presented in Table S1.
(TIF)
Figure S2 The effect of RJ-Fr.2 on the lifespan of C. elegans. The
survival curves of N2 hermaphrodites incubated with RJ-Fr.2 (0
(control), 10, 25 or 100 mg/ml) are shown. The RJ-Fr.2 was given
at 20uC from 0-day adult until death. Day 0 corresponds to the L4
molt. The percentage of live worms is plotted against adult age.
Detailed parameters are presented in Table S1.
(TIF)
Figure S3 The effect of pRJ-Fr.5 treatment on DAF-16 nuclear
translocation. DAF-16 nuclear translocation was examined in a
daf-16::gfp transgenic N2 line (zIs356, TJ356). The animals were
treated with pRJ-Fr.5 (0 or 25 mg/ml) for 24 hrs. [A] Images of
DAF-16::GFP animals. The arrowheads show the nuclear
localization of DAF-16::GFP. [B] The translocation of DAF-
16::GFP into the intestinal nuclei was not seen in untreated
animals, whereas a fraction of pRJ-Fr.5-treated animals exhibited
DAF-16::GFP translocation. The percentage of animals with
nuclear-localized (black) and diffuse (gray) DAF-16::GFP in
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treated).
(TIF)
Table S1 Effects of RJ or pRJ on the lifespan.
(XLSX)
Table S2 Differentially regulated genes by pRJ-Fr.5 treatment.
(XLSX)
Table S3 Effects of 10-HDA and/or pRJ-Fr.5 on the lifespan.
(XLSX)
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